Atezolizumab (Tecentriq): Where the PD-L1 Pioneer Stands

Atezolizumab, sold as Tecentriq, was the first PD-L1 inhibitor approved by the FDA. Unlike pembrolizumab and nivolumab, which block PD-1, it blocks the ligand, and it has built a position in several specific settings.

Mechanism at a glance

Atezolizumab is an engineered IgG1 antibody against PD-L1 that blocks its interaction with both PD-1 and B7.1. Because it targets the ligand, it leaves the PD-L2/PD-1 interaction intact, a difference that has been discussed for years but whose clinical significance remains debated.

Where it plays

• Lung cancer: both non-small cell and small cell, in combination with chemotherapy, and as adjuvant therapy in selected NSCLC. In extensive-stage small cell lung cancer it is also used with lurbinectedin as maintenance therapy (IMforte, approved October 2025).
• Liver cancer: with bevacizumab in unresectable hepatocellular carcinoma, a regimen later challenged by other combinations.
• Bladder and colon cancer: adjuvant use in ctDNA-positive muscle-invasive bladder cancer was approved in May 2026 (IMvigor011), and an adjuvant colon cancer application (ATOMIC) has an FDA action date of October 9, 2026.

A subcutaneous formulation, Tecentriq Hybreza, was approved by the FDA in September 2024 and supports convenience in busy infusion centers.

The competitive context

Atezolizumab competes with the PD-1 leaders and with other PD-L1 agents such as durvalumab and avelumab. Its trajectory shows how important differentiation is in a crowded class: its strongest positions tend to come from combination regimens and specific tumor types rather than from a broad checkpoint-inhibitor label.

What CI teams should track

1. Anti-TIGIT combinations: Roche discontinued its own program, tiragolumab, in July 2025 after Phase 3 failures.
2. Competing regimens in hepatocellular carcinoma.
3. Adjuvant and perioperative lung cancer uptake.
4. Loss of exclusivity timelines and biosimilar activity.

Compare with pembrolizumab and nivolumab for the wider class view.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Jun 2026: FDA granted Priority Review to Tecentriq or Tecentriq Hybreza plus FOLFOX6 as adjuvant therapy for stage III dMMR/MSI-H colon cancer (ATOMIC, an NCI/Alliance trial of 712 patients), with an action date of October 9, 2026. Roche reports a 50% reduction in the risk of recurrence or death and 36-month DFS of 86% vs 76%. (Roche)
• May 15, 2026: FDA approved Tecentriq and Tecentriq Hybreza as adjuvant therapy for ctDNA-positive muscle-invasive bladder cancer after cystectomy (IMvigor011, 250 patients): DFS of 9.9 vs 4.8 months (HR 0.64) and OS of 32.8 vs 21.1 months (HR 0.59). The approval is paired with the Signatera companion diagnostic. (ONS Voice)
• Oct 2, 2025: FDA approved lurbinectedin plus atezolizumab (or atezolizumab/hyaluronidase) as first-line maintenance in extensive-stage small cell lung cancer after induction (IMforte, 483 patients): median OS of 13.2 vs 10.6 months (HR 0.73) and PFS of 5.4 vs 2.1 months. (Targeted Oncology)
• Jul 2025: Roche discontinued tiragolumab after SKYSCRAPER-14/IMbrave152 (first-line liver cancer) failed on PFS, with reported median PFS of 8.3 vs 8.2 months and no overall survival trend. (ApexOnco)
• Sep 12, 2024: FDA approved Tecentriq Hybreza (atezolizumab with hyaluronidase) across Tecentriq’s adult IV indications; injection takes about seven minutes vs 30-60 minutes for IV. It is described as the first subcutaneous PD-(L)1 inhibitor. (Drugs.com)
• Sep 6, 2024: Roche withdrew its EU application to extend Tecentriq plus bevacizumab to adjuvant liver cancer, saying the updated IMbrave050 results were insufficient to support it. (EMA)

Upcoming catalysts

• Oct 9, 2026: FDA action date for adjuvant Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer. As of October 8, no decision had been announced.

Bottom line

Atezolizumab’s story is one of focused positioning. Its value to a franchise lies in specific combinations and settings, so a CI team should follow it indication by indication, not as a generic member of the checkpoint class.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.